Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • emc易倍官网入口Press Releases
    • emc易倍官网入口Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • emc易倍官网入口Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  •         EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • emc易倍官网入口Asia Pacific
    • Europe
    • emc易倍官网入口Middle East & Africa
    • Brazil
    • emc易倍官网入口 Canada
    • United States
    • emc易倍官网入口 Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • emc易倍官网入口 Ukraine
    • UK
    • emc易倍官网入口 Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • emc易倍官网入口 Czech Republic
    • emc易倍官网入口 Romania
    • Hungary
    • Slovakia
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • emc易倍官网入口Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • emc易倍官网入口Clinical Trials
      • emc易倍官网入口Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • emc易倍官网入口Environment
    • emc易倍官网入口Patients
    • People
    • Governance
    • emc易倍官网入口Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • emc易倍官网入口Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. emc易倍官网入口Newsroom – Newsroom – Subscribe to Ipsen News

emc易倍官网入口

IPN price

€158.40

 €-2.20 (-1.37%)

  • Media Resources
  • emc易倍官网入口Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • emc易倍官网入口Cookie Policy
  • emc易倍官网入口Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?






2026-07-15 13:41:25